BioCentury
ARTICLE | Company News

FDA committee to discuss Novartis' serelaxin

January 8, 2014 1:30 AM UTC

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Feb. 13 to discuss a BLA from Novartis AG (NYSE:NVS; SIX:NOVN) for serelaxin ( RLX030) to treat acute heart failure (AHF). The recombinant human relaxin 2 (RLN2; H2)has FDA breakthrough therapy designation for the indication and is under review in Europe. ...